All data are based on the daily closing price as of October 8, 2025
h

HK inno.N

195940.KQ
32.65 USD
0.74
+2.32%

Overview

Last close
32.65 usd
Market cap
924.96M usd
52 week high
38.09 usd
52 week low
21.69 usd
Target price
44.25 usd

Valuation

P/E
N/A
Forward P/E
N/A
Price/Sales
1.5437
Price/Book Value
1.0191
Enterprise Value
1.17B usd
EV/Revenue
1.7075
EV/EBITDA
18.5738

Key financials

Revenue TTM
588.94M usd
Gross Profit TTM
244.22M usd
EBITDA TTM
66.91M usd
Earnings per Share
N/A usd
Dividend
0.25 usd
Total assets
1.43B usd
Net debt
283.49M usd

About

HK inno.N Corporation engages in the pharmaceutical business in South Korea. The company offers prescription drugs for the treatment of gram-positive and gram-negative organisms, enterococcus faecium infections, vancomycin-resistant, acute bacterial sinusitis, bronchitis, neumonia, antibiotics, and infections caused by microorganism; anemia and hemodialysis; diabetes; hypertension, primary hypercholesterinemia, homozygous familial hypercholesterolemia, and hypertension with dyslipidemia; GERD, EE, NERD, GU and H.Pylori; pleural mesothelioma, non-small cell lung cancer, and mesothelioma, and colorectal cancer; and nutrition and intravenous nutrition. It also provides health and beverage products, such as hangover relief, ready to drink, health supplements and health functional foods, as well as active pharmaceutical ingredients. In addition, the company offers beauty products under the bewants, ScalpMed, and KLEDERMA RX brands. It also exports its products to Japan, Southeast Asia, Latin America, Europe, and the Middle East countries. HK inno.N Corporation was founded in 1984 and is headquartered in Cheongju-si, South Korea.
  • Symbol
    195940.KQ
  • Exchange
    KQ
  • Isin
    N/A
  • Country
    South Korea
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - Specialty & Generic
  • CEO
    Mr. Dal-Won Kwak
  • Headquarter
    Cheongju-si
  • Web site
    https://www.inno-n.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top